Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression

The tumor necrosis factor (TNF) antagonist infliximab was recently found to reduce depressive symptoms in patients with increased baseline inflammation as reflected by a plasma C-reactive protein concentration >5mg/L. To further explore predictors and targets of response to infliximab, differenti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mehta, Divya, Raison, Charles L., Woolwine, Bobbi J., Haroon, Ebrahim, Binder, Elisabeth B., Miller, Andrew H., Felger, Jennifer C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673885/
https://ncbi.nlm.nih.gov/pubmed/23624296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbi.2013.04.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak